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Abstract: Background: Many pediatric transplant (TX) centers routinely monitor Epstein-Barr (EB) viral load (VL) by
real time quantitative PCR and intervene to prevent post-transplant lymphoproliferative disorder (PTLD). Some children
develop asymptomatic persistent VL (PVL). Outcome of different interventions in preventing PTLD and other undesired
effects on acute rejection (AR), graft failure (GF) and function amongst children with asymptomatic PVL is not known.
Methods: NAPRTCS centers invited to enter data on children with asymptomatic PVL (≥ 6 months) into the EB VL
registry. Comparison group included children into the NAPRTCS TX arm during the same period without PVL or VL
monitoring. EB VL were arbitrarily divided into low (1-10), medium (>10-100) and high (>100times detection limit for
the center) ratio.
Results: Of 645 children (18 centers), 85 (13.2%) developed onset of PVL at a mean of 6.4 ± 6.3 months post-TX. PVL
children were more likely to be younger (< 5 years) at TX and less likely to be African-American and majority (75.3%)
was mismatched for EBV (donor EBV IgG positive and recipient negative). Thymoglobulin induction was used in 29.4%
children with PVL versus 37% in controls (p=ns). PTLD developed in 7/85 (8.2%) children with PVL versus 5/560
(0.9%) controls (p < 0.0001). EB VL ratios were not different in those with and without PTLD. EB PVL as time varying
covariate did not affect patient survival, GF and AR (HR, 0.85, 0.53 and 0.99). The change in GFR overtime in children
with PVL was comparable to controls.
Conclusion: Children with PVL (actual load not predictive) are at increased risk for PTLD, but not for AR, death, GF or
loss of graft function.

Keywords: Children, Epstein-Barr virus, kidney transplantation.
BACKGROUND
Post-transplant lymphoproliferative disorder (PTLD) is a
serious complication in Epstein Barr virus (EBV) naïve
children [1]. Most cases of PTLD are EBV driven and have
evidence of EBV infection at diagnosis [2]. With the
widespread availability of Epstein Barr (EB) viral load (VL)
assays by real time quantitative polymerase chain reaction
(RT-qPCR) for clinical purposes, many pediatric centers
have adopted routine surveillance of their post-transplant
patients for early detection of EB VL by RT-qPCR [3]. This
strategy has led to detection of children with asymptomatic
EB VL including a subset with persistent VL (PVL). Often,
transplant nephrologists make immunosuppression (IS)
*Address correspondence to this author at the Division of Pediatric
Nephrology, Washington University School of Medicine & St. Louis
Children’s Hospital, Campus Box 8116, Room NWT 10-119, 660 South
Euclid Avenue, St Louis, MO 63110, USA; Tel: 314-286-1574;
Fax: 314-286-2351; E-mail: Dharnidharka_V@kids.wustl.edu
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adjustments and add other therapies (antiviral medications,
intravenous immunoglobulin, cytogam, and rituximab) to
decrease EB VL in order to prevent PTLD. However,
excessive reduction of IS may lead to acute rejection
(AR)and graft dysfunction. Outcome of pediatric patients
with asymptomatic EB PVL and these interventions is not
well characterized. In pediatric heart transplant (TX)
recipients, 45% children with PVL developed PTLD [4]. In
contrast, the rate of progression to PTLD was less than 10%
in pediatric liver transplant recipients [5]. In this study, we
sought to ascertain the incidence of PVL and progression
rate to PTLD in pediatric kidney transplant recipients, as
well as the impact of different interventions on patient and
graft survival and graft function. This data was collected
from 18 pediatric transplant centers participating in the
North American Pediatric Renal Trials and Collaborative
Studies Report (NAPRTCS) registry.
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METHODS
NAPRTCS is a voluntary consortium of pediatric
nephrology centers in the United States and Canada with the
aim of standardized data collection on patients with chronic
kidney disease, those receiving dialysis and after transplant
to help provide pediatric specific benchmarking data to
improve quality of care for these children. The data elements
collected and methodology are described in the NAPRTCS
annual report [6]. The data is entered on line in a password
protected database. All participating centers (144) have
approval of their respective institutional review boards to
enter data into this registry.
EB PVL Registry
EB PVL registry was newly created for this study within
the NAPRTCS, as data on EB VL was not originally
collected in the NAPRTCS transplant arm. Each
participating center routinely measuring post-transplant EB
VL by RT-q PCR was asked to enter additional information
on their patients with EB PVL into this registry and given a
small reimbursement for each completed form. Patients
meeting the following inclusion criteria were eligible for
participation in the EB PVL registry: 1. Transplant after
January 1, 2005, 2. those with persistent (≥2 positive VL or
≥2/3 of measured VL positive over 6 months) EB VL, 3.
asymptomatic (no symptoms of EBV infection or PTLD
prior to first VL detection and over 6 months afterwards
during viral surveillance), 4. follow-up of at least 1 year after
fulfilling criteria for EB PVL. After data entry was
completed, the first author sought clarifications from the
participating centers through telephone interviews and email
communications. Other patients enrolled into NAPRTCS
transplant arm without PVL or VL monitoring from these 18
centers during the same time served as controls. Of note,
some of these control patients may have had transient VL or
progressed to PTLD within 6 months of EB VL detection.
Data Collected
Data on demographics, EBV and cytomegalovirus
(CMV) serologies of the donor and recipient at transplant,
induction therapies (monoclonal, polyclonal antibody
thymoglobulin
and
no
induction),
maintenance
immunosuppression, type of specimen for EB VL assay
(whole blood, plasma, serum or lymphocytes), and VL
detection limit of each laboratory was collected. The
frequency of monitoring of EBV VL was 1-3 months and in
case of more frequent monitoring in case of positive VL,
centers were asked to enter only one (highest) value per
month. In addition, type of intervention after detection of
first EB VL (reduction in immunosuppression, antiviral
medications, intravenous immunoglobulin and rituximab),
information on PTLD, patient and graft survival, acute
rejection and graft function was collected. Estimated
Glomerular filtration rate (eGFR) was calculated by using
modified old Schwartz formula described in the NAPRTCS
annual report. As there were different assays used for
measuring EB VL in different centers, EB VL ratio using the
peak viral load value over 6 months period (measured VL in
the specimen/VL detection limit for the laboratory) was
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calculated and arbitrarily divided into low (1-10), medium
(>10-100) and high (>100). The incidence of PTLD was
compared amongst children with different VL ratios to
assess if incidence of PTLD increased with increasing VL.
Statistics
Demographics and categorical variables between EB
PVL and controls were compared by chi-square analysis.
Cox regression model with development of EB PVL used as
time varying covariate adjusted for age, race and gender was
used to compare patient survival, graft survival, time to acute
rejection and to PTLD between those with EB PVL and
controls. A repeated measures linear regression analysis also
adjusted for age at transplant, race and gender was used to
compare eGFR during follow-up between EB PVL and
controls. P value of <0.05 was considered significant. All
analyses were conducted using SAS version 9.2 (Cary, NC).
RESULTS
Incidence of Asymptomatic EB PVL
Eighteen pediatric transplant institutions participating in
this study enrolled 645 children in the NAPRTCS transplant
arm from January 2005-April 2011. Of these, 85 were
reported to have EB PVL (Cumulative incidence 13.2%,
incidence at each center ranged range between 2.7-32%).
Onset of EB PVL was first detected at a mean ±SD of 6.4±
6.3 (median 4.2, range 0-35.5) months after transplant.
Viral Load Assays
Of 18 centers, 13 centers (68 children) had EB VL
measurement in the whole blood (detection limits of 60-2000
copies/ml), 4 centers (10 children) in the plasma (detection
limits of 120-250 copies/ml), 2 centers (5 children) in the
serum (detection limits of 100-2000 copies/ml), 1 center (2
children) in the lymphocytes (detection limit 150 copies/105
lymphocytes). Note that 2 centers had more than one type of
measurement.
Risk Factors for EB PVL
Young (<5 years of age) and Caucasian children were
more likely to develop PVL. Thymoglobulin induction was
not identified as a risk factor for PVL (Table 1). As data on
the CMV and EBV serostatus was not available in the
control group since these data are not routinely collected in
the master transplant registry, CMV and EBV mismatched
status could not be compared between children with PVL
and controls. However, of children with EB PVL, 55/73
(75.3%) were mismatched (Donor + and recipient –) for
EBV IgG and 37/80 (46.3%) were mismatched for CMV
IgG. The data were missing for the remaining children.
Peak Viral Load Ratio Over 6 Months and Induction
Therapy in EBV Mismatched Children
Comparison of peak median VL ratio over 6 months in
children receiving induction therapy with Thymoglobulin to
those with anti-IL-2R antibodies in EBV mismatched

EB Viral Load Monitoring and PTLD
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Risk factors for EB persistent viral load.

Risk Factors

PVL
N (%)
85 (13.2)

Controls
N (%)
560 (86.8)

P-Value

Age <5 years

34 (40.0)

83 (14.8)

<0.0001

Male

44 (51.8)

328 (58.6)

NS

Caucasian

53 (62.4)

295 (52.7)

A-A

10 (11.8)

123 (22.0)

Thymoglobulin

25 (29.4)

207 (37)

Anti-IL-2 R

31 (36.4)

170 (30.4)

No induction

27 (31.7)

132 (23.6)

Other induction/Combination therapies

2 ( 2.4)

51 (9)

0.025

Peak VL Ratio
Over 6 Months

Thymoglobulin
N (%)

Anti-IL-2 R
N (%)

N

21

27

2 (9.5)

2 (7.4)

4 (19.1)

12 (44.4)

15 (71.4)

13 (48.2)

1500

92

1-10
Medium
>10-100
High
>100
Median VL

Peak EBV VL ratio in patients with and without
PTLD in EBV PVL group.

NS

Peak EB VL over 6 months and induction therapy in
EBV mismatched children.

Low

(p=0.0001). PTLD developed at a mean of 16.4 ± 8.9 (median 15, range 8-33) months after TX in the EB PVL group
and at a mean of 7.5 ± 1.7 (median 8.4, range 5.4-8.8) months
after TX in the control group. Amongst 85 children with
PVL, 0/5 (0.0%) with low, 3/30 (10.0%) with medium and
4/50 (8%) with high VL ratio developed PTLD (Table 3).
Amongst children with PVL, 4/7 (57.1%) with PTLD and 41
/78 (52.6%) children without PTLD had reduction in IS
(p=ns). Antiviral therapy was used in 1/7 (14.2%) children
with PTLD versus in 15/78 (19.2%) without PTLD (p=ns).
Table 3.

children is shown in Table 2. Seven children receiving
induction with other agents or no induction were excluded
from this analysis. Though median VL ratio was higher in
children who received induction therapy with Thymoglobulin compared to those with anti-IL-2R antibodies (1500
versus 92, p 0.044), the proportion of those with low,
medium and high VL ratio was not different in the two
groups (p=0.179).
Table 2.
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Chi-square p-value = 0.179.
Median test p-value = 0.044.

Intervention in EB PVL Patients
Of 85 children in the category of EB PVL, 45 (52.9%)
had reduction or discontinuation of IS. Of 45 children, 19
(42.2%) had 20-66% reduction in the dose of Mycophenolate
mofetil (MMF) or Azathioprine (AZA), whereas 26 (57.8%)
children discontinued MMF or AZA. The CNI dose was
reduced by 9-71% in 52 (62.2%) children and discontinued
in 1 child. In 20 (23.5%) children anti-viral medications
were used; Valganciclovir was used for 1 month->3 years in
17 children and Cytogam was used in 3 children. In 3
children, 2-4 doses of Rituximab were used.
PTLD
Of 645 children in the study, 12 developed PTLD with
the overall incidence of 1.9%. Seven of 85 (8.2%) with PVL
versus 5/560 (0.9%) control children developed PTLD

Peak VL Ratio
Before PTLD*

Non-PTLD
N (%)

PTLD
N (%)

N

78

7

5 (6.4)

0 (0.0)

27 (34.6)

3 (42.9)

46 (59.0)

4 (57.1)

161

138

Low
1-10
Medium
>10-100
High
>100
Median VL

*In patients not developing PTLD, the peak VL over the course of follow-up was used.
Chi-square p-value = 0.750.
Median test p-value = 0.719.

PTLD in PVL Group
Of 7 children with PTLD, 5 developed PTLD within 1
year of fulfilling diagnostic criteria for PVL. Of these, 2 had
received induction with thymoglobulin and 5 received with
anti-IL-2R antibodies. Of these, 3 children had PTLD limited
to tonsils and adenoids and were treated with further
reduction in IS, 4 doses of rituximab and removal of tonsils
and adenoids. Three children had PTLD limited to lymph
nodes, 2 were treated with further reduction in IS, and 4
doses of Rituximab and one with decrease in IS alone. One
child developed PTLD involving central nervous system and
was treated with further reduction in IS, rituximab (16
doses), followed by chemotherapy. All children with PTLD
were alive with functioning graft at last follow up.
Effect of EB PVL on the Patient and Graft Survival,
Acute Rejection and Graft Function
EB PVL as time varying covariate adjusted for age, race
and gender showed no impact on patient and graft survival or
acute rejection (Table 4). However, it was strongly
associated with risk of subsequent development of PTLD
(Table 4 and Fig. 1). The slope of change in eGFR over time
was not different in children with EB PVL and controls (Fig.
2).
DISCUSSION
Our data shows that routine monitoring of EB VL by RTqPCR identifies a group of children with asymptomatic PVL
that is at risk for subsequent development of PTLD despite
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varying degree of empiric interventions. The incidence of
PTLD amongst these children with PVL was 8.2%, much
higher than the overall incidence of 1.9% in this study and
overall reported incidence of PTLD (mostly 1%) amongst
children after renal transplantation [7]. In this study young,
Caucasian and EBV mismatched children were more likely
and African-American children were less likely to develop
PVL. These demographic and clinical characteristics have
been identified as risk factors for PTLD in the previous
studies; however, these characteristics have not been
previously assessed for development of EB PVL [1, 8-10].
Table 4.

Effect of EB PVL(Time Varying Covariate adjusted
for Age, Race and Gender) on patient and graft
survival, acute rejection and PTLD.

Cox Regression

HR

95% CI

p-Value

Patient Survival

0.85

0.10- 7.61

0.88

Graft Failure

0.53

0.20- 1.38

0.19

Acute Rejection

0.99

0.56-1.75

0.98

PTLD

11.05

3.30-37.05

<0.0001
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antibodies in increasing risk for PTLD [12], perhaps due to
intermixing of ALG and equine ATG (Atgam) with rabbitATG (Thymogloubulin). When Thymoglobulin has been
assessed separately from the other polyclonal antibodies, the
risk for PTLD has not been elevated [13]. The role of
Thymoglobulin in EB PVL has not been previously assessed.
Though the NAPRTCS lumps all polyclonal antibodies into
one group, our data pertains to Thymoglobulin as during the
time period of this study, the only polyclonal antibody being
used for induction is Thymoglobulin and the older agents
ALG and Atgam are no longer being used for renal
transplant recipients.

Fig. (2). Change in eGFR overtime in controls and those with EB
PVL. Shows change in GFR overtime in children with EB PVL and
controls. The slope of change in eGFR was not different.

Fig. (1). Percent without PTLD in controls and those with EB PVL.
Kaplan Meier graph showing percentage of children without PTLD
overtime amongst children with EB PVL and controls. More
children in PVL group developed PTLD overtime. All children with
PTLD in the control group developed it in the first 9 months of
transplantation.

Concern has been raised that thymoglobulin may play a
role in the development of PTLD as it has been shown to
deplete poly functional T cells in HIV infected kidney
transplant recipients and activate EBV replication [11]. Even
though the median VL was high in EBV mismatched
children receiving induction with thymoglobulin, it was not
identified as a risk factor for a higher proportion of children
developing EB PVL in this study. Previous studies have
provided mixed results regarding the role of polyclonal

In our control group, 5 children developed PTLD within
the first 9 months post-TX (Fig. 1). Of these, 4 were not
prospectively monitored and EB VL was not detected in one.
However, all children had evidence of EBV infection on
histologic examination. It is plausible that prospective
monitoring in these children may have detected EB VL, as
negative predictive value of EB VL for EBV infection is
high [14]. However, it is unlikely that these children would
have qualified for PVL since the time period between TX
and PTLD was rather short (7.5 ± 1.7 months).
RT-qPCR to measure EB VL varies across different
centers with 4 different type of specimens (whole blood,
plasma, serum and lymphocytes) used with different
laboratory cut-off values. We tried to tackle this problem by
calculating VL ratio as intra-laboratory variation is small
[15]. RT-qPCR is the most sensitive method available for
viral quantitation [16, 17]. The type of specimen needed for
best clinical correlation with EB VL has not been settled.
Since EBV causes proliferation of B-cells in the latent stage,
cell based assays (whole blood and lymphocytes) provide
estimation of B-cell proliferation induced by latent EBV,
whereas plasma and serum assays reflect either EBV actively
released from the B-cells in the replicating phase or passive
release of latent EBV from breakdown of EBV infected B-

EB Viral Load Monitoring and PTLD
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cells. Though EB VL measurement in the whole blood was
the most commonly used assay in this study (68 of 85
children), the actual peak VL was not helpful in predicting
PTLD. A recent study by Hocker et al. did not find
correlation between EB VL and duration of VL with PTLD
or EBV associated diseases [18]. Thus, this study and that by
Hocker et al. show that EB PVL alone has a low predictive
value for PTLD. However, prospective EBV VL monitoring
improves predictability of PTLD over no monitoring at all. It
was also reassuring that none of the 5 children with low VL
developed PTLD. Additional assays including measurement
of EBV specific cytotoxic T-cells generation [19] or B-cell
dysfunction [20] in addition to measurement of EB VL has
been suggested to help refine prediction of PTLD. However,
these assays need further validation for clinical purposes.

Vikas R. Dharnidharka: Study design and manuscript
writing.

Reduction of IS has been the cornerstone of preventing
PTLD [21]. However, there are no guidelines on how to
reduce IS safely in children with EB PVL to prevent PTLD,
while not increasing the risk for AR, graft loss or graft
dysfunction. In this study, we could not show the difference
in the incidence of PTLD amongst children with PVL who
had decrease in IS versus those who did not. This may be
related to the small number of PTLD cases. However, it was
reassuring that decrease in IS did not lead to increased
incidence of AR, graft loss and graft dysfunction suggestive
of the fact that these children were likely to be over
immunosuppressed. However, we did not assess the risk of
developing de novo donor specific antibodies (DSA) after
reduction in IS which may compromise graft function in the
future. Antiviral medications have been suggested to
decrease PTLD, but effect of antivirals could not be assessed
due to small number of children receiving antivirals and low
incidence of PTLD in this study [22].
Limitations of this study include retrospective registry
data analysis, lack of uniform control arm (including both
monitored and not monitored children and possibility of
including some children with transient VL), and lack of
standardization of EBV assays though we tried to address the
later by calculating VL ratio.
In conclusion, EB PVL develops in a subset of children
(most mismatched for EBV) after renal transplantation.
Young, Caucasian and EBV mismatched children are at risk
for PVL, whereas thymoglobulin induction does not confer
increased risk. Children with moderate to high PVL (actual
load not predictive) are at risk for PTLD despite empiric
interventions but not at increased risk for AR, death, GF or
loss of graft function. There is a need for standardization of
EB VL assays and interventions including immunologic
monitoring for DSA development to fully elucidate the role
of EB PVL in pediatric renal transplant recipients.
Additional assays of EBV specific T-cell cytotoxicity and or
B-cell function are needed to help further define the risk of
PTLD amongst children with EB PVL.
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AZA

= Azathioprine
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= Cytomegalovirus
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= Calcineurin inhibitor

EBV

= Epstein Barr Virus

eGFR

= Estimated glomerular filtration rate

IS

= Immunosuppression

IVIG

= Intravenous immunoglobulin

MMF

= Mycophenolate mofetil

NAPRTCS = North American Pediatric Renal Trials and
Collaborative Studies Report
PTLD

= Post-transplant lymphoproliferative disorder

PVL

= Persistent viral load

RT-qPCR

= Real time quantitative polymerase chain
reaction

VL

= Viral Load
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